User:Mr. Ibrahem/Aflibercept

Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and colorectal cancer which has spread to other parts of the body. For colon cancer it is given together with fluorouracil, leucovorin, and irinotecan. It is used by injection into the eye or by intravenous infusion.

Common side effects when used in the eye include subconjunctival bleeding, eye pain, and cataracts. Common side effects when used for cancer include low white blood cells, diarrhea, increased liver enzymes, and low platelets. Other side effects when used for cancer include bleeding, gastrointestinal perforation, and poor wound healing. It is an inhibitor of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).

Aflibercept was approved for medical use in Europe and the United States in 2012. For the eye it is initially given once a month with a dose of medication costing about 1,950 USD in the United States as of 2021. In the United Kingdom this amount costs the NHS about 41£. When used for cancer, 4 ml of 25 mg/ml solution costs about 1,680 USD as of 2021 in the USA and 296£ in the UK.